Cancer diagnosis used to hinge almost entirely on the trained eye of a radiologist or pathologist, working scan by scan, slide by slide. That model is now being layered — not replaced, but sharpened — by algorithms that can flag a suspicious lesion in milliseconds or predict a chemotherapy dose from a CT scan's fat, bone, and muscle composition. That shift is exactly what's fueling the AI in oncology market, valued at USD 6.0 billion in 2025 and on track to hit USD 38.9 billion by 2033, expanding at a CAGR of 24.8% from 2026 onward.

Numbers this steep usually signal one of two things: a speculative bubble, or a genuine infrastructure shift in how an entire discipline operates. Cancer AI looks far closer to the second. Every major driver behind this growth — rising cancer incidence, FDA clearances crossing the 690-device mark, precision-medicine adoption — points to a field embedding AI into its clinical backbone rather than experimenting at the margins.

What's Actually Driving This Market

Cancer incidence is outpacing the world's diagnostic capacity. GLOBOCAN's 2022 estimate of 19.9 million new cancer cases worldwide — with Asia Pacific alone contributing 9.8 million — has exposed a hard bottleneck: there simply aren't enough radiologists and pathologists to read every scan and slide at the speed diagnosis now demands. AI-based systems that automate segmentation, quantification, and pattern recognition are filling that capacity gap before a specialist ever reviews the case.

Imaging is where AI earns its keep first. Ultrasound, MRI, CT, and PET data feed AI models that pre-process routine detection work, letting radiologists focus on the judgment calls machines still can't make. In a survey of researchers publishing on AI and cancer, close to a third pointed to radiology as the field with the greatest 10-year AI upside, with pathology close behind at roughly 27%. That's a telling signal — the people writing the research believe imaging and diagnostics, not administrative or scheduling tools, are where AI's clinical value concentrates.

Regulatory momentum has stopped being a bottleneck and started being an accelerant. DermaSensor's January 2024 FDA clearance for skin cancer detection was a watershed moment — it validated that AI-native devices, not just AI-assisted software layered onto existing hardware, can clear the same bar as traditional medical devices. Since then, FDA data shows over 690 AI-enabled devices have been authorized, cleared, or approved in the U.S. alone, compounding trust and adoption in a feedback loop.

Precision medicine has given AI a second growth lane beyond detection. Tools like Penn Medicine's iStar — which reads gene activity in tissue images to spot tertiary lymphoid structures linked to immunotherapy response — show where the market is heading next: not just "does this patient have cancer," but "which specific treatment will actually work for this specific tumor." That distinction matters because it moves AI from a diagnostic support role into a therapy-selection role, a far higher-value clinical function.

Download a free sample report or claim your copy of this full market intelligence report

Where the Money Is Actually Going: Key Market Segments

By component, hardware currently leads — but the momentum is shifting. Hardware held 39.4% share in 2025, largely because AI-embedded imaging equipment and processing units carry the biggest price tags and the deepest procurement cycles. But software solutions are set to grow fastest through 2033. That's a normal maturity curve: capital-heavy hardware gets bought once and used for years, while software — priced on subscriptions, updated constantly, and infinitely more scalable across hospital systems — compounds faster once the hardware base is in place.

Breast cancer dominates by cancer type, prostate cancer is catching up fastest. Breast cancer held 20.9% of the market in 2025, tracking directly with its status as the most diagnosed cancer among women in the U.S. (an estimated 297,790 cases per NIH data). But prostate cancer — affecting roughly 13 in 100 U.S. men — is the fastest-growing segment, driven by tools like Quibim's QP-Prostate cutting detection processing time while improving accuracy. Watch this segment closely: fast-growing-but-not-yet-dominant categories are usually where the next wave of company launches and partnerships concentrates.

Diagnostics leads applications today; R&D is the one to watch. Diagnostics accounted for 37% share in 2025 — the natural entry point for any AI clinical tool, since detection is where the largest, most standardized datasets already exist. But research & development is forecast to grow fastest, as machine learning gets folded into drug discovery, target identification, and clinical trial design. This is arguably the more consequential long-term shift: AI moving upstream from "reading the results" to "designing the treatment" changes the market's entire value structure, because R&D tools sell into pharma and biotech budgets that dwarf hospital procurement cycles.

Hospitals remain the center of gravity for end use, commanding 48% share in 2025 and also posting the fastest forward growth — an unusual combination that signals hospitals aren't just early adopters but sustained, expanding buyers as digitalization deepens across their diagnostic and treatment workflows.

Regionally, North America holds 45.8% share, built on strong reimbursement policy and digital health infrastructure, while Asia Pacific is the fastest-growing region, propelled by rising cancer burden and rapid diagnostic-lab digitization across China and India.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

The Insight Competitors Are Missing

Most coverage of this market treats "AI in oncology" as a single growth story. It isn't. It's two overlapping markets moving at different speeds: a mature, hardware-and-diagnostics market that's already embedded in hospital procurement cycles, and an emerging, software-and-R&D market that's still being built out. The companies worth watching — Lunit's Middle East expansion, MVision AI's international clearances, ConcertAI's CancerLinQ acquisition — are the ones straddling both, using diagnostic-market revenue to fund R&D-market bets. For buyers, investors, and health systems alike, the real strategic question isn't "should we adopt AI in oncology" — that decision is already made across most large hospital networks. It's which layer of the stack — imaging hardware, diagnostic software, or drug-discovery R&D — offers the best entry point for the resources and timeline you actually have.

The Cost Reality Nobody Skips Past Fast Enough

None of this comes cheap. Total AI healthcare implementation costs run anywhere from USD 20,000 to USD 1 million, layering software licensing, hardware integration, dedicated technical teams, and ongoing maintenance. With limited government subsidy in most markets, private hospitals and health systems absorb the bulk of that cost directly — which is precisely why hospital-segment growth, despite already leading end use, still has headroom: institutions large enough to spread that capital outlay across patient volume gain a durable diagnostic edge over smaller providers who can't.

Where This Leaves the Market

The AI in oncology market isn't waiting for proof of concept anymore — it's scaling proven use cases across geographies and cancer types while building the next layer, from liquid biopsies detecting brain cancer through blood-based DNA fragments to voice-analysis apps flagging early-stage lung cancer. The organizations positioned to capture the next leg of this 24.8% CAGR are the ones treating AI not as a bolt-on diagnostic tool, but as infrastructure spanning detection, treatment selection, and drug discovery simultaneously.

Explore our dedicated business services:

• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage. 

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services.  Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.